News
Discontinuation of Levemir® (insulin detemir)
Levemir® insulin, in both its Penfill® and Flexpen® presentations, is to be discontinued, with an anticipated supply end date of December 2026. A Medicine Supply Notification (MSN/2025/036U) has been ...
Wockhardt’s Hypurin Porcine 10ml insulin vials to be discontinued
A Medicine Supply Notification has been issued by the Department of Health and Social Care about the discontinuation of Wockhardt’s Hypurin Porcine insulin range in 10ml vials. The notification, issue...
SGLT-2 inhibitors to become first-choice treatments for type 2 diabetes
Draft NICE guidelines propose upgrading Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors from second choice to first-choice treatments for type 2 diabetes. The updated draft guideline, ‘Type 2 di...
Teplizumab authorised by the MHRA
The first ever immunotherapy for type 1 diabetes has now been licensed for use in the UK. The Medicines and Healthcare products Regulatory Agency (MHRA) has confirmed teplizumab, also known as Tzield,...
Portable, easy to use device a promising new tool for cardiac autonomic neuropathy screening
NerveCheck Master could be a potential new screening tool for cardiac autonomic neuropathy, following promising results from a recent study. The international study set out to evaluate the accuracy of...
Programme unveiled for international diabetic neuropathy conference
Experts in diabetic neuropathy will share their research and specialist knowledge at NEUROdiab’s35th Annual Meeting in September. Billed as “the most important yearly event in diabetic neuropathy”, th...
New diabetes safety board guide launched by GIRFT
GIRFT has produced a guide to support clinical teams in establishing diabetes safety boards. This follows a recommendation in GIRFT’s national specialty report on diabetes, published in November 2020...
Inhaled insulin as safe and effective as injected for children, study indicates
An inhaled form of rapid-acting insulin is a safe and effective alternative to injected insulin for children and adolescents with diabetes, according to study results presented at the American Diabete...
Experimental weight-loss drug shows mostly mild side effects in trials
Full data from two major Phase 3 trials of Novo Nordisk’s investigational weight-loss treatment show that most side effects were mild to moderate, with positive outcomes reported for weight reduction ...